Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 May 19;14:2861. doi: 10.1038/s41467-023-38581-8

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2023

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 6 — a Representative immunofluorescence images and quantification of BODIPY staining of lipid droplet in parental and resistant GX006 GC organoids treated with DMSO, 5FU + CDDP, SSI4 and combination of 5FU + CDDP and SSI4 (COMBO). Scale bar, 50 μm (low magnification) and 20 μm (high magnification). b Representative immunofluorescence images and quantification of ER tracker staining in the indicated treatment groups in GX006 parental and GX006 5FU + CDDP resistant organoids. Scale bar, 50 μm. c Western blot analysis for expression of ER stress markers including total and phosphorylated eIF2α, ATF4, and CHOP upon indicated treatment groups in GX006 parental and GX006 5FU + CDDP resistant organoids. β-actin is used as loading control. d Representative immunofluorescence images and quantification of BODIPY staining of lipid droplet in the indicated treatment groups in GX006 parental and GX006 5FU + CDDP resistant xenografts. e Haematoxylin and eosin (H&E) and IHC staining for phosphorylated eIF2α and ATF4 in the indicated treatment groups in GX006 parental and GX006 5FU + CDDP resistant xenografts. Scale bar, 100μm. (a) n = 4 independent experiments; (b) n = 3 independent experiments. (c) n = 3 independent experiments; (d) n = 10-12 randomly captured field of view. Parental-DMSO, Resistant-DMSO, Resistant-5FU + CDDP, n = 12 images; Parental-5FU + CDDP, n = 11 images; Resistant-SSI4 and Resistant-COMBO, n = 10 images. (e) n = 8-10 randomly captured field of view. For p-eIF2α, Parental-DMSO, Parental-5FU + CDDP, Resistant-DMSO, Resistant-5FU + CDDP, Resistant-SSI4, n = 9 images; Resistant-COMBO, n = 8 images. For ATF4, Parental-DMSO and Resistant-5FU + CDDP, n = 10 images; Parental-5FU + CDDP, Resistant-DMSO and Resistant-SSI4, n = 9 images; Resistant-COMBO, n = 8 images. Significance were calculated by (a, b) two-way ANOVA; (d, e) one-way ANOVA. Data was presented as mean ± standard deviation. COMBO for combination, IRS for immunoreactive score, MFI for mean fluorescence intensity. ns for not significant. Source data are provided as a Source Data file.